Mathew Minardi | Chief Operating Officer and President Americas

1 min read 26th Mar 2025

Mathew Minardi PhD, BS

Chief Operating Officer and President Americas

Mat is our Chief Operating Officer and President Americas.

Mat has a PhD in organic chemistry and has previously held Vice President roles at Accord Healthcare, Johnson and Johnson’s Noramco and Ampac Fine Chemicals. He has extensive experience of API development projects, global team leadership and company operations and growth in the pharmaceutical CDMO market.

Education

Arizona State University, 2002, PhD, Synthetic Chemistry
Clemson University, 1997, BS, Chemistry

Publications

An Efficient Synthetic Strategy for Obtaining 4-Methoxy Carbon Isotope Labeled Combretastatin A-4 Phosphate and Other Z-Combretastatins December 2009

Human cancer and other clinical trials under development employing combretastatin A-4 phosphate (1b, CA4P) should benefit from the availability of a [(11)C]-labeled derivative for positron emission tomography (PET).
Antineoplastic Agents. 509. Synthesis of Fluorcombstatin Phosphate and Related 3-Halostilbenes November 2005

The present SAR study of combretastatin A-3 (3a) focused on replacement of the 3-hydroxyl group by a series of halogens. That approach with Z-stilbenes resulted in greatly enhanced (>10-100-fold) cancer cell growth inhibition against a panel of human cancer cell lines and the murine P388 lymphocytic leukemia cell line.
Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs January 2001

A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (10a-l) was readily achieved.

Sterling Resources

Facility overview video: North Carolina, US February 2025

In this video, we take a look at the five things you should know about our North Carolina, US facility.
Top ten early phase considerations December 2021

Early phase API discovery and development is exceedingly challenging, requiring careful consideration of many complex variables, some of which will only come into play in latter stages of the pharmaceutical lifecycle.
Early phase API discovery and development December 2021

Early phase API discovery and development is among the most challenging and exciting chapters of a molecule’s journey to market.
Making sense of funding support October 2021

The right outsourced partner can provide the guidance and expertise organisations need to secure critical funding in support of their molecules’ development.

Affiliations

American Chemical Association